Wegovy – (Semaglutide) 2.4 mg Pre-Filled Pen: Maintenance Dose for Weight Management

Introduction Wegovy (semaglutide) 2.4 mg pre-filled pen is the highest approved maintenance dose of this once-weekly GLP-1 receptor agonist for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Each single-use disposable pen delivers a fixed 2.4 mg dose in 0.75 mL solution and is supplied in cartons of 4 pens for one month of treatment. Manufactured by Novo Nordisk, this pen is designed for long-term use after successful titration through lower doses. It is prescription-only; the following information is educational—consult your healthcare provider for personalised advice and monitoring.

Mechanism of Action Semaglutide mimics the incretin hormone GLP-1, activating receptors to enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and powerfully reduce appetite via central nervous system pathways. At the full 2.4 mg maintenance dose, these effects reach their peak, producing strong satiety, reduced calorie intake, and sustained metabolic improvements. Its approximately one-week half-life supports consistent weekly dosing with stable plasma levels.

Key Potential Benefits At 2.4 mg, clinical trials (STEP program) demonstrated: • Average weight loss of 15–17% of initial body weight over 68 weeks (often 30–40+ lbs / 14–18+ kg). • Significant reductions in waist circumference, visceral fat, and cardiometabolic risk factors. • Improved blood pressure, lipid profiles, and glycemic control. • Better quality of life, physical function, and sustained appetite control when combined with reduced-calorie diet and increased physical activity. Many participants achieved ≥15% or even ≥20% weight loss, with benefits maintained during continued treatment.

Dosage and Administration for the 2.4 mg Pen Each pen is pre-set for a single 2.4 mg dose with an integrated hidden needle for simple subcutaneous injection. Inject 2.4 mg once weekly on the same day each week, at any time, with or without food. Preferred sites are the abdomen, thigh, or upper arm; rotate sites weekly. Full titration schedule leading to maintenance:

Weeks 1–4: 0.25 mg
Weeks 5–8: 0.5 mg
Weeks 9–12: 1.0 mg
Weeks 13–16: 1.7 mg
From week 17 onward: 2.4 mg maintenance (or remain at 1.7 mg if 2.4 mg is not tolerated) If a dose is missed for more than 5 days, skip it and resume the regular schedule. Store unopened pens in the refrigerator; after removal, they can be kept at room temperature (<30°C) for up to 28 days. Dispose of used pens safely in a sharps container.

Potential Side Effects Gastrointestinal effects are most frequent at the 2.4 mg dose: nausea, vomiting, diarrhea, constipation, abdominal pain, or heartburn. These are usually mild to moderate but can be more noticeable initially at the maintenance dose. Other common effects include fatigue, headache, or injection-site reactions. Serious but rare risks include pancreatitis, gallbladder problems, severe stomach issues, or allergic reactions. Wegovy carries a boxed warning for the risk of thyroid C-cell tumors and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2. Regular monitoring by a healthcare provider is essential.

Conclusion The Wegovy 2.4 mg pre-filled pen delivers the full therapeutic maintenance dose proven to drive clinically significant, sustained weight loss and metabolic improvements. When used as directed after proper titration, combined with lifestyle changes, it offers one of the most effective non-surgical options for long-term weight management. Source only from licensed pharmacies, follow the prescribed schedule, and maintain regular medical supervision. Responsible use maximises benefits while minimising side effects